Dr Srija Moulik
Contact information
Research groups
Srija Moulik
Senior Research Technician
In my role on the UKRI-funded PITCH Study (Protective Immunity for T cells in Healthcare Workers in Oxford), I focus on investigating T cell immunity in COVID-19. My core responsibilities include isolating and cryopreserving peripheral blood mononuclear cells (PBMCs), plasma, and serum from fresh blood samples provided by study volunteers. Additionally, I am involved in pooling and properly storing peptides for use in T cell assays and assessing T-cell responses through ELISpot assays using frozen PBMCs from human blood samples, specifically from patients with SARS-CoV-2 and RSV.
Beyond these tasks, I systematically organize samples, maintain detailed sample inventories, and coordinate the shipment of samples to academic collaborators. I ensure that research findings are clearly documented and kept up to date, and I stay informed about recent research articles relevant to my work to deepen my understanding. I also regularly communicate updates and results to my line manager and engage in discussions on experimental outcomes with colleagues at the Institute. Moreover, I participate in various seminars, workshops, and courses hosted by the department and University to support my professional development.
Address:
Peter Medawar Building for Pathogen Research
University of Oxford
South Parks Road
Oxford
OX1 3SY
UK
Recent publications
-
Molecular monitoring of treatment efficacy in human visceral leishmaniasis.
Roy S. et al, (2024), Transactions of the Royal Society of Tropical Medicine and Hygiene, 118, 343 - 345
-
Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis.
Dey NS. et al, (2024), The Journal of clinical investigation, 134
-
Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).
Wijnant G-J. et al, (2024), Experimental parasitology, 257
-
Does immune dysregulation contribute towards development of hypopigmentation in Indian post kala-azar dermal leishmaniasis?
Sengupta R. et al, (2023), Experimental dermatology, 32, 740 - 751
-
Liposomal amphotericin B is more effective in polymorphic lesions of post kala-azar dermal leishmaniasis.
Moulik S. et al, (2022), Indian journal of dermatology, venereology and leprology, 88, 201 - 206